磺胺多辛-乙胺嘧啶加阿莫地喹与双氢青蒿素-哌喹在乌干达季节性疟疾化学预防中的效果:一项三臂、开放标签、非劣效与优效性、整群随机对照试验
在乌干达Karamoja地区3-59月龄儿童中开展的整群随机对照试验显示,磺胺多辛-乙胺嘧啶加阿莫地喹(SPAQ)和双氢青蒿素-哌喹均显著降低疟疾风险,分别降低94%和96%,且双氢青蒿素-哌喹对SPAQ为非劣效;未报告严重或致死性不良事件,无耐药选择证据。
要点
- SPAQ和双氢青蒿素-哌喹分别降低疟疾风险94%和96%,均优于无SMC对照。
- 双氢青蒿素-哌喹对SPAQ在预设非劣效界值1.4下为非劣效(HR 0.90)。
- 未报告严重或致死性不良事件,未发现SMC选择耐药证据。
核心结论
- SPAQ和双氢青蒿素-哌喹有效降低5岁以下儿童疟疾,无安全性担忧,无耐药选择证据。
- 尽管结果支持在东非和南部非洲使用基于SPAQ的SMC,持续耐药监测和疗效监测对维持效果至关重要。
研究设计与样本
- 三臂、开放标签、非劣效与优效性、整群随机对照试验,在乌干达Karamoja次区域开展。
- 380个村随机(1:1)分配至SPAQ组和双氢青蒿素-哌喹组,47个村分配至对照组(无SMC)。
- 纳入3-59月龄(SPAQ)和6-59月龄(双氢青蒿素-哌喹)儿童,2022年6月18-30日入组3881名儿童,3629名纳入分析。
- 主要终点为经快速诊断试验或显微镜确诊的疟疾发病率,采用意向性治疗生存分析并调整基线协变量不平衡。
- 对750份5岁以下疟疾阳性血样分析磺胺多辛-乙胺嘧啶和阿莫地喹耐药分子标记。
主要发现
- 疟疾发病率:SPAQ组0.90例/100人月,双氢青蒿素-哌喹组0.80例/100人月,对照组18.26例/100人月。
- SPAQ降低疟疾风险94%(HR 0.06 [95%CI 0.04-0.08];p<0.001),双氢青蒿素-哌喹降低96%(HR 0.04 [95%CI 0.03-0.06];p<0.001)。
- 基于预设非劣效界值1.4,双氢青蒿素-哌喹对SPAQ为非劣效(HR 0.90 [95%CI 0.58-1.39])。
- 中度和高度磺胺多辛-乙胺嘧啶耐药相关突变患病率分别>88%和<5%,4-氨基喹啉耐药相关突变<1%。
- 未报告严重或致死性不良事件。
关键数值与推荐
- 非劣效界值为1.4。
- SPAQ组发病率0.90例/100人月,双氢青蒿素-哌喹组0.80例/100人月,对照组18.26例/100人月。
- SPAQ的HR 0.06(95%CI 0.04-0.08;p<0.001),双氢青蒿素-哌喹的HR 0.04(95%CI 0.03-0.06;p<0.001)。
- 双氢青蒿素-哌喹对比SPAQ的HR 0.90(95%CI 0.58-1.39)。
临床怎么用
- 作者认为结果支持在东非和南部非洲使用基于SPAQ的SMC。
- 作者指出持续耐药监测和疗效监测对维持效果至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine combined with amodiaquine (SPAQ) effectively protects eligible children from malaria in areas of high and seasonal transmission. However, concerns about parasite resistance to sulfadoxine-pyrimethamine in East and Southern Africa necessitate evaluating alternative drug regimens. This study assessed the effectiveness of SPAQ and dihydroartemisinin-piperaquine for SMC in Uganda. METHODS: This three-arm, open-label, non-inferiority and superiority, cluster-randomised, controlled trial was conducted in Karamoja subregion, Uganda, among children aged 3-59 months and 6-59 months for SPAQ and dihydroartemisinin-piperaquine, respectively. Of 427 villages, 380 were randomly assigned (1:1) to the SPAQ group and dihydroartemisinin-piperaquine group, and 47 were assigned to the control group (no SMC). The superiority component compared the SPAQ and dihydroartemisinin-piperaquine groups with the control group, whereas the non-inferiority component compared the dihydroartemisinin-piperaquine group with the SPAQ group. The primary endpoint was confirmed malaria incidence using rapid diagnostic tests or microscopy. Survival analyses were done on an intention-to-treat basis (in all randomised participants), with adjustments made for covariate imbalances at baseline. Additionally, molecular markers associated with resistance to sulfadoxine-pyrimethamine and amodiaquine were analysed on 750 malaria-positive blood samples from children younger than 5 years before and after five SMC cycles. This trial was registered with ClinicalTrials.gov, NCT05323721, and has been completed. FINDINGS: During June 18-30, 2022, 3881 children were enrolled; 1755 in SPAQ, 1736 in dihydroartemisinin-piperaquine, and 390 in control villages. Of these children, 3629 were analysed. Incidence rates were 0·90 cases per 100 person-months in the SPAQ group, 0·80 cases per 100 person-months in the dihydroartemisinin-piperaquine group, and 18·26 cases per 100 person-months in the control group. SPAQ and dihydroartemisinin-piperaquine reduced malaria risk by 94% (hazard ratio [HR] 0·06 [95% CI 0·04-0·08]; p<0·001) and 96% (0·04 [0·03-0·06]; p<0·001), respectively. Based on the prespecified non-inferiority margin of 1·4, there was non-inferiority between the protective effectiveness of dihydroartemisinin-piperaquine and that of SPAQ (HR 0·90 [95% CI 0·58-1·39]). Prevalence of mutations linked to moderate (Plasmodium falciparum dihydrofolate reductase [PfDHFR] and P falciparum dihydropteroate synthetase reductase [PfDHPS]) and high (PfDHFR Ile164Leu and PfDHPS Ala581Gly) sulfadoxine-pyrimethamine resistance were more than 88% and less than 5%, respectively. Mutations associated with 4-aminoquinolone resistance (P falciparum multidrug resistance protein-1 [PfMDR1] Asp1246Tyr and PfMDR1 Asn86Tyr) were less than 1%. There was no significant increase in the prevalence of antifolate and artemisinin partial resistance-associated mutations, but a decrease was observed for key aminoquinoline resistance-associated alleles: P falciparum chloroquine resistance transporter protein Lys76Thr, P falciparum multidrug resistance protein Asn86Tyr, and PfMDR1 Asp1246Tyr (p<0·001). No serious or fatal adverse events were reported. INTERPRETATION: SPAQ and dihydroartemisinin-piperaquine effectively reduced malaria in children younger than 5 years, with no safety concerns. There was no evidence of resistance selection by SMC. Although these findings support SPAQ-based SMC in Eastern and Southern Africa, ongoing resistance surveillance and efficacy monitoring are essential for sustained impact. FUNDING: GiveWell. TRANSLATION: For the Swahili translation of the abstract see Supplementary Materials section.
引用
- Nuwa A, Baker K, Kajubi R, et al. Effectiveness of sulfadoxine-pyrimethamine plus amodiaquine and dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in Uganda: a three-arm, open-label, non-inferiority and superiority, cluster-randomised, controlled trial. Lancet Infect Dis. 2025. PMID: 39826559. doi:10.1016/S1473-3099(24)00746-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。